← Back to Analyst Consensus 
RXRX Buy
RECURSION PHARMACEUTICALS, INC.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 11, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| May 14, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| May 7, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Apr 30, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Feb 26, 2026 | B of A Securities | maintain | Neutral → Neutral | $6 | 53% |
| Feb 26, 2026 | Needham | reiterate | Buy → Buy | $8 | 50% |
| Dec 17, 2025 | JP Morgan | upgrade | Neutral → Overweight | $11 | 55% |
| Sep 11, 2025 | Needham | reiterate | Buy → Buy | $8 | 50% |
| Jul 8, 2025 | Needham | reiterate | Buy → Buy | $8 | 50% |
| Jun 16, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $5 | 54% |
| May 6, 2025 | Needham | maintain | Buy → Buy | $8 | 50% |
| Apr 10, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $8 | 54% |
| Apr 8, 2025 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Feb 28, 2025 | Leerink Partners | maintain | Market Perform → Market Perform | $6 | 51% |
| Feb 6, 2025 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Jan 8, 2025 | Keybanc | maintain | Overweight → Overweight | $10 | 52% |
| Dec 11, 2024 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Nov 20, 2024 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Nov 7, 2024 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Sep 4, 2024 | Needham | maintain | Buy → Buy | $11 | 50% |
| Sep 3, 2024 | Jefferies | maintain | Hold → Hold | $6 | 52% |
| Sep 3, 2024 | Leerink Partners | maintain | Market Perform → Market Perform | $8 | 51% |
| Aug 9, 2024 | Needham | maintain | Buy → Buy | $16 | 50% |
| Jul 11, 2024 | Keybanc | maintain | Overweight → Overweight | $12 | 52% |
| Jun 25, 2024 | Needham | reiterate | Buy → Buy | $17 | 50% |
| May 10, 2024 | Needham | reiterate | Buy → Buy | $17 | 50% |
| Apr 9, 2024 | Needham | reiterate | Buy → Buy | $17 | 50% |
| Mar 4, 2024 | Keybanc | maintain | Overweight → Overweight | $16 | 52% |
| Feb 28, 2024 | Needham | maintain | Buy → Buy | $17 | 50% |
| Jan 26, 2024 | TD Cowen | initiate | — → Market Perform | $0 | 54% |
| Jan 17, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Jan 16, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Nov 13, 2023 | JP Morgan | maintain | Neutral → Neutral | $10 | 55% |
| Nov 9, 2023 | Needham | maintain | Buy → Buy | $15 | 50% |
| Sep 5, 2023 | Needham | reiterate | Buy → Buy | $17 | 50% |
| Aug 9, 2023 | Needham | reiterate | Buy → Buy | $17 | 50% |
| Jul 21, 2023 | Needham | reiterate | Buy → Buy | $17 | 50% |
| Jul 18, 2023 | Needham | reiterate | Buy → Buy | $17 | 50% |
| Jul 13, 2023 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $11 | 54% |
| Jul 13, 2023 | Keybanc | maintain | Overweight → Overweight | $15 | 52% |
| Jul 12, 2023 | Needham | reiterate | Buy → Buy | $17 | 50% |
| Jul 12, 2023 | Berenberg | reiterate | Buy → Buy | $33 | 29% |
| May 9, 2023 | Needham | reiterate | — → Buy | $17 | 50% |
| May 9, 2023 | Keybanc | maintain | — → Overweight | $12 | 52% |
| Apr 18, 2023 | Needham | reiterate | — → Buy | $17 | 50% |
| Mar 16, 2023 | Needham | initiate | — → Buy | $17 | 50% |
| Jan 23, 2023 | SVB Leerink | maintain | — → Market Perform | $8 | — |
| Nov 9, 2022 | Goldman Sachs | maintain | — → Neutral | $9 | 54% |
| Oct 25, 2022 | SVB Leerink | maintain | — → Market Perform | $9 | — |
| Sep 16, 2022 | Keybanc | initiate | — → Overweight | $20 | 52% |
Price Target Trend
Jul 19, 2026 Oct 27, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days